Abstract
The natural product hymenialdisine was first isolated in 1980 from the marine sponges of the genera Hymeniacidon, Acanthella, Axinella and Pseudaxinyssa. The structure was elucidated on the basis of X-ray crystallography demonstrating a structurally interesting pyrrole-azepin-8-one ring system bonded to a glycocyamidine ring. Great interest has been taken in synthesizing this type of scaffold due to its potent activity in competitive kinase inhibition. In addition, several patents have claimed pharmacological use of these compounds for prevention and treatment of different diseases. The challenging syntheses of hymenialdisine and its analogues are described in this review as well as their evaluation as kinase inhibitors.
Keywords: Natural products, marine sponge metabolites, hymenialdisine, kinase inhibitors, chemotherapy
Current Medicinal Chemistry
Title: Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors
Volume: 16 Issue: 24
Author(s): T. N.T. Nguyen and J. J. Tepe
Affiliation:
Keywords: Natural products, marine sponge metabolites, hymenialdisine, kinase inhibitors, chemotherapy
Abstract: The natural product hymenialdisine was first isolated in 1980 from the marine sponges of the genera Hymeniacidon, Acanthella, Axinella and Pseudaxinyssa. The structure was elucidated on the basis of X-ray crystallography demonstrating a structurally interesting pyrrole-azepin-8-one ring system bonded to a glycocyamidine ring. Great interest has been taken in synthesizing this type of scaffold due to its potent activity in competitive kinase inhibition. In addition, several patents have claimed pharmacological use of these compounds for prevention and treatment of different diseases. The challenging syntheses of hymenialdisine and its analogues are described in this review as well as their evaluation as kinase inhibitors.
Export Options
About this article
Cite this article as:
Nguyen N.T. T. and Tepe J. J., Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors, Current Medicinal Chemistry 2009; 16(24) . https://dx.doi.org/10.2174/092986709788803015
| DOI https://dx.doi.org/10.2174/092986709788803015 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Interventional Radiology in Paediatrics
Current Pediatric Reviews Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Editorial [Hot Topic: Hydrolase Versus Other Functions of Members of the Alpha/Beta-Hydrolase Fold Superfamily of Proteins (Guest Editor: Pascale Marchot and Arnaud Chatonnet)]
Protein & Peptide Letters MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Review of Pediatric Uveitis
Current Pediatric Reviews Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued)

